Narrow search
Showing 1 - 10 of 1,437
Cover Image
Erratum
Adis International Limited - In: PharmacoEconomics 30 (2012) 1, pp. 81-81
Persistent link: https://www.econbiz.de/10009421259
Cover Image
Do Productivity Costs Matter?: The Impact of Including Productivity Costs on the Incremental Costs of Interventions Targeted at Depressive Disorders
Krol, Marieke; Papenburg, Joc; Koopmanschap, Marc; … - In: PharmacoEconomics 29 (2011) 7, pp. 601-619
Background:Background: When guidelines for health economic evaluations prescribe that a societal perspective should be adopted, productivity costs should be included. However, previous research suggests that, in practice, productivity costs are often neglected. This may considerably bias the...
Persistent link: https://www.econbiz.de/10011005068
Cover Image
Is There a Role for Pharmacoeconomics in Developing Countries?
Harper, Jonathan R. - In: PharmacoEconomics 29 (2011) 5, pp. 435-436
Persistent link: https://www.econbiz.de/10011005069
Cover Image
Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer: A Systematic Review
Bongers, Mathilda L.; Coupé, Veerle M.H. Coup; Jansma, … - In: PharmacoEconomics 30 (2012) 1, pp. 17-34
In past decades, studies focusing on new chemotherapeutic agents for patients with inoperable non-small-cell lung cancer have reported only modest gains in survival. These health gains are achieved at considerable cost, but economic evidence is lacking on superiority of one agent in terms of...
Persistent link: https://www.econbiz.de/10011005070
Cover Image
Cost of Illness of Cystic Fibrosis in Germany: Results from a Large Cystic Fibrosis Centre
Heimeshoff, Mareike; Hollmeyer, Helge; Schreyogg, Jonas … - In: PharmacoEconomics 30 (2012) 9, pp. 763-777
identify variables influencing different cost categories. A sensitivity analysis using Monte Carlo simulation was performed … for drug costs per patient as the dependent variable. Monte Carlo simulation suggests that there is a 90% probability that …
Persistent link: https://www.econbiz.de/10011005071
Cover Image
Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets
Augestad, Liv Ariane; Rand-Hendriksen, Kim; … - In: PharmacoEconomics 30 (2012) 12, pp. 1203-1214
Background:Background: National EQ-5D value sets are developed because preferences for health may vary in different populations. UK values are lower than US values for most of the 243 possible EQ-5D health states. Although similar protocols were used for data collection, analytic choices...
Persistent link: https://www.econbiz.de/10011005072
Cover Image
Impact of Treatment Success on Health Service Use and Cost in Depression: Longitudinal Database Analysis
Byford, Sarah; Barrett, Barbara; Despiégel, Nicolas … - In: PharmacoEconomics 29 (2011) 2, pp. 157-170
Background: Research has consistently demonstrated a relationship between depression and increased levels of health service use over the short term. However, much less is known about how this relationship is influenced by the success, or otherwise, of depression management strategies, and the...
Persistent link: https://www.econbiz.de/10011005073
Cover Image
Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium
Hiligsmann, Mickal; Reginster, Jean-Yves - In: PharmacoEconomics 29 (2011) 10, pp. 895-911
Background: Denosumab has recently been shown to be well tolerated, to increase bone mineral density (BMD) and to significantly reduce the risk of hip, vertebral and non-vertebral fractures in the FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial. It is...
Persistent link: https://www.econbiz.de/10011005074
Cover Image
Medical Resource Utilization and Cost of HIV-Related Care in the Highly Active Antiretroviral Therapy Era at a University Clinic in Sweden
Ghatnekar, Ola; Hjortsberg, Catharina; Gisslén, Magnus … - In: PharmacoEconomics 28 (2010) S1, pp. 49-57
Introduction: Little is known regarding healthcare costs for HIV/AIDS patients in the era of highly active antiretroviral therapy (HAART) and subgroups of patients according to the severity and progression of HIV infection in Sweden. The objective of this study is therefore to describe the...
Persistent link: https://www.econbiz.de/10011005075
Cover Image
Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis
Soares, Marta O.; Canto e Castro, Lusa - In: PharmacoEconomics 30 (2012) 12, pp. 1101-1117
approximations can be used: simulation models in continuous time and discretized models at the aggregate level. Stylized examples … if lower cycle lengths are used. Continuous time simulation models are inherently stochastic, and the precision of the … results is determined by the simulation sample size. The use of continuity corrections in discretized models allows the use of …
Persistent link: https://www.econbiz.de/10011005076